BioCare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) and FISH (Fluorescent in situ hybridization) instrumentation and reagents, acquired BroadOak portfolio company Empire Genomics, a market leader in molecular biomarkers to aid in cancer research and diagnostics. The transaction brings an expansive molecular product suite and custom genomic biomarker development capabilities to BioCare.
The full press release is below.
November 22, 2022 – Biocare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) and FISH (Fluorescent in situ hybridization) instrumentation and reagents, announces the acquisition of Empire Genomics, a market leader in molecular biomarkers to aid in cancer research and diagnostics.
Empire Genomics is a premier designer, manufacturer and distributor of a comprehensive menu of clinical and custom-labeled molecular probes, enabling thousands of leading global research facilities, clinical laboratories, and biotechnology organizations to advance biomarker research, accelerate diagnoses and improve personalized treatment options for patients battling cancer and other complex diseases. Empire Genomics technology has been cited in over 500 hundred peer-reviewed scientific publications.
“This acquisition complements our broad portfolio of IHC antibodies, robust molecular menu and advanced automation platforms,” said Biocare Medical CEO Luis de Luzuriaga. “The addition of Empire Genomics will enable the acceleration of research and advance cancer diagnostics for better patient outcomes.”
Empire Genomics’ innovative portfolio of molecular probes empowers thousands of leading clinical laboratories, biotechnology companies and academic institutions around the world. Since 2006, Empire Genomics has built a legacy of high quality, molecular technology and proven their ability to deliver products that improve genetic research and patient care consistently.
“The breadth of the Empire Genomics portfolio is well-suited for automation on Biocare Medical’s ONCORE Pro and ONCORE Pro X platforms to produce high-quality, reproducible FISH and CISH results.” said Jason Ramos, Vice President of Research and Development at Biocare Medical. “Combining Empire Genomics’ rapid turnaround time for new biomarker development with ONCORE Pro’s accelerated hybridization opens myriad opportunities for cancer research applications.”
Together, Biocare Medical and Empire Genomics will bring an expanded offering of solutions to those researching and diagnosing cancer around the world.
Stay connected
Partner with BroadOak